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Shistologic grade, lymphovascular invasion, number of pos-
itive lymph nodes, pathologic N-classification, depth of
cancer invasion.Discussion
Dr David R. Jones (Charlottesville, Va). I thank the Associa-
tion for the opportunity to discuss this fine paper. I have no disclo-
sures related to the discussion. It is a pleasure to review and then
discuss yet another paper from Dr Raja and colleagues from the
Cleveland Clinic Foundation. As we are all aware, the Cleveland
Clinic and, in particular, the senior author of this paper, Dr Rice,
have been leaders in the surgical treatment of esophageal cancer,
and this presentation certainly adds value to our understanding
of the pathobiology of the disease. Dr Raja, I have 3 questions
for you, and I will ask them 1 at a time.
First, given that the submucosal layer is measured to be roughly
half a millimeter, how difficult is it in measuring thewidth and sub-
sequent depth of mucosal invasion by the pathologists? It strikes
me that this may be quite subjective. What are your comments
with respect to this issue?
Dr Raja. Our pathologists tell us the submucosa varies from
200 to 1000 mm. Although there is a degree of subjectivity, di-
viding it into thirds has not been a problem for our and other pa-
thologists. Submucosal cancers have a defined prevalence of
regional lymph node metastases, and even invasion of the inner
third of the submucosa is associated with meaningful lymphatic
metastases.
Dr Jones. Second, how does the information that you have pre-
sented affect your clinical decision making when your initial endo-
scopic ultrasound report classifies the T stage as T1a or T1b?
Would you now advocate a transthoracic approach and perhaps
a more aggressive mediastinal node dissection versus, for instance,
a transhiatal?
Dr Raja.We rely on endoscopic ultrasound to identify submu-
cosal (T1b) cancer. In patients in whom the clinical differentiation
of intramucosal from submucosal cancer is uncertain, we use en-
doscopic mucosal resection and pathologic review of that speci-
men. We believe that endoscopic therapies should be reserved
for no more than intramucosal cancer.
We have previously published that a minimum of 10 lymph
nodes need to be resected and examined to maximize 5-year
survival in patients with T1 cancer.* This frequently requires
a transthoracic approach. This study has taught us that long, circum-
ferential, poorly differentiated cancers and those cancers with lym-
phovascular invasion are more likely to have deep submucosal
invasion and thus a very high rate of regional lymph nodemetastases.
Today these findings would dictate a transthoracic approach. In our
study, 60% of patients had a transthoracic approach and 40% had
a transhiatal approach, and there was no survival difference.
Dr Jones. Thank you. You actually addressed my last question
with how this relates to endoscopic mucosal resection.*Rizk N, Venkatraman E, Park B, Flores R, Bains MS, Rusch V; American Joint
Committee on Cancer staging system. The prognostic importance of the number
of involved lymph nodes in esophageal cancer: implications for revisions of the
American Joint Committee on Cancer staging system. J Thorac Cardiovasc
Surg. 2006;132:1374-81.
1410 The Journal of Thoracic and Cardiovascular SurDr Hiran Fernando (Boston, Mass). Dr Raja, that was an
excellent presentation. You showed a couple of slides that cor-
related depth of invasion with grade and with length and with
the area of the tumor that you see. Those would be much easier
end points to measure preoperatively if you were contemplat-
ing doing a submucosal resection or an endoscopic resection
for these patients. Do you know what the outcomes are for
those 3 things—the grade, the length, and the area—related
to things such as survival and incidence of occult nodal
disease?
Dr Raja. By univariable analysis, all of these factors were
found to be significant for regional lymph node metastases. Be-
cause of the interplay among these factors, multivariable analysis
identified only one important predictor of regional lymph node
metastases: deep submucosal invasion. Subsequent survival was
related to the presence of regional lymph node metastases. Al-
though one could use these other factors that were significant in
univariable analysis, the most reliable factor for clinical decision
making is deep submucosal invasion.
Dr Wayne L. Hofstetter (Houston, Tex). I congratulate you on
a nice presentation. I have a couple of questions. You mentioned
that the D2-40 marker was used. Did you go back retrospectively
and look for submucosal invasion with the D2-40 marker or immu-
nohistochemistry or, secondarily, on the older specimens, did you
rereview for lymphovascular invasion?
Dr Raja.We did not use the D2-40 marker. Our pathologists re-
viewed all hematoxylin and eosin slides for lymphovascular
invasion.
Dr Hofstetter. When we rereviewed our slides with a second
pathologist, we found that we upstaged to lymphovascular inva-
sion about 10% of the time, so that was interesting to us.
The second question was regarding patients that manifested su-
perficial submucosal invasion. You had 8% that were lymph node
positive. How many of those patients were lymphovascular inva-
sion positive or lymphovascular invasion negative? This informa-
tion has implications in terms of the applicability of endoscopic
mucosal resection.
Dr Raja. Forty-six percent of patients with lymphovascular in-
vasion had regional lymph node metastases as opposed to 18%
without regional lymph node metastases. For patients with only in-
ner submucosal invasion, lymphovascular invasion was present in
none with lymph node metastasis and 11% without lymph node
metastasis, a reflection of 8% prevalence of regional lymph node
metastasis.
Dr Hofstetter. Finally, in terms of the patients that were T1b,
N1, you revealed that overall survival was 36% at 5 years. I am
not surprised that there was no difference in your approach surgi-
cally from transthoracic to transhiatal, because this is a marker, as
you are indicating, of watershed or systemic disease. Because we
are having such poor outcomes with these T1b, N1 patients, are
you considering neoadjuvant therapy for this group of patients if
they could be identified preoperatively?
Dr Raja.When regional lymph node metastasis is found at re-
section, we offer our patients postoperative adjuvant therapy. Pre-
operatively, if regional lymph node metastasis is detected in
patients with submucosal cancer, neoadjuvant therapy is pre-
scribed. For the majority of patients with submucosal cancer, neo-
adjuvant therapy is excessive.gery c December 2011
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SDr Toni Lerut (Leuven, Belgium). Dr Raja, thank you very
much and congratulations for an original study. We have done
a similar study on a similar number of patients. We found
a much higher incidence of positive lymph nodes in the more su-
perficial layer, as well as in the deeper layers, than displayed by the
data that you showed. This was true particularly in squamous but
also in adenocarcinoma, up to 33% positive nodes for the superfi-
cial layer. You said that you had 40% transhiatal esophagectomies
and 60% transthoracic esophagectomies. I suspect that you have
done proportionally more transhiatal resections for the more super-
ficial carcinomas that also happened to be smaller carcinomas. We
all know that the more nodes you remove, the greater the chance
for positive nodes. Could you give us more insight in that respect?
What was the number of removed nodes?
Dr Raja. The median number of lymph nodes resected was 14
(10 with the transhiatal approach and 18 with the transthoracic ap-
proach). A transthoracic approach was used in 50% of patients
with inner cancers, 62% with middle cancers, and 71% with
deep cancers. Eleven percent had squamous cell cancer, too few
to analyze. Your supposition that transhiatal resection was used
less frequently for cancer with deeper invasion is correct. There-
fore, it is possible that resecting more regional lymph nodes for
less invasive cancer may reveal a higher prevalence of lymph
node metastases in this group.
Dr Lerut. We in fact had 30 as a mean.
My second question relates to the survival curves. You showed
that older age is doing worse, but that is probably because this is
a curve showing the overall survival. Wouldn’t it be better to show
disease-free survival,which is amore cancer-specific survival curve?
Dr Raja. Cancer-specific mortality is a soft end point, and can-
cer recurrence is similarly problematic. For these reasons, we use
all-cause mortality.
Dr Sebastien Gilbert (Ottawa, Ontario, Canada). Thank you
for your excellent presentation. I would like to know whetherThe Journal of Thoracic and Carendoscopic mucosal resection is routine in your evaluation of these
patients inasmuch as endoscopic ultrasound alone, even with the
highest resolution probe, has difficulty distinguishing between
mucosal and submucosal lesions. Second, in the case of intramu-
cosal esophageal cancer arising in the background of dysplastic
Barrett esophagus, is there an acceptable threshold in the probabil-
ity of lymph node metastases below which you may consider en-
doscopic resection and ablation with close follow-up, and
beyond which you would recommend esophageal resection?
Dr Raja.We do not routinely use endomucosal resection in pa-
tients with submucosal cancer. Endomucosal resection is used to
differentiate between deep intramucosal and superficial submuco-
sal invasion. Because of the unacceptable prevalence of regional
lymph node metastases in any patient with submucosal cancer,
we recommend that they undergo an esophagectomy.
Dr Stephen Cassivi (Rochester, Minn). I will make 2 points.
One is to congratulate your group again for parsing out the esoph-
ageal wall in a way that we have not seen before. You have taken an
area that is 500 to 1000 mm in depth and given us a lot of
information.
Second, I would like to emphasize, and maybe you can con-
firm this, that there is 10% lymphovascular invasion in just the
superficial part of the submucosa and an 8% lymph node metas-
tases. The true divide, from a therapeutic standpoint, is there-
fore at the muscularis mucosa. In terms of minimally invasive
or endoscopic treatments versus a surgical treatment, I think
that lymph node metastases rate is too high to allow for ade-
quate treatment from an endoscopic standpoint. Would you
agree?
Dr Raja. Undeniably, submucosal cancers have an exponen-
tially increasing prevalence of regional lymph node metastases
with increasing depth of invasion. Alarmingly, 8% of inner submu-
cosal cancers have regional lymph node metastasis. We agree that
the muscularis mucosa is an important divide for therapy.diovascular Surgery c Volume 142, Number 6 1411
